At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 154 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Ruxolitinib 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib for Myelofibrosis and 2 related conditions. Completed, enrolled 154 participants across 2 sites.
Detailed Summary
To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia Myelofibrosis (PET-MF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelofibrosis, Polycythemia Vera, Thrombocytosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedAug 2007
Primary CompletionDec 2007
Study CompletionFeb 2017
TodayJul 2026
First PostedAug 1, 2007
Enrollment StartJun 1, 2007
Primary CompletionDec 1, 2007
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.9 years ago
Interventions
Ruxolitinibdrug
5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.